In the premarket trading session, ZosanoPharma Corporation (ZSAN) shares had plunged at last check by -3.27% to trade at the price of $0.977. ZSAN stock had previously closed the session on Tuesday while gaining 3.02% to close at $1.01. In the past 50 days, the ZSAN stock average volume of trading has been 2.44 million which is greater than today’s volume traded of 1.28 million shares. In the past year up to date has ZSAN shares rising by 24.23% and in the past week the shares have moved up by 9.30%. In the past three and six months, the stock has shed-12.17% and added 66.45%.

What you need to know about ZosanoPharma Corporation

ZosanoPharma Corporation is a biotechnology company that is specifically a clinical stage biopharma as well. ZSAN stock focuses on the production and provision of unique and novel treatments as well as therapeutics to meet the unmet needs of clients that are both health-workers and patients. The company has a platform where it develops therapeutics to reduce migraine for suffering patients along with other bioactive molecules which can work through using a transdermal microneedle system. The company’s lead investigative product candidate is used for the acute treatment of migraines. It is known as Qtrypta (M207) which is a proprietary formulation of zolmitriptan. The company was established in 2006 and is based in Fremont, California.

ZosanoPharma Corporation is a leading biopharma that is specializing in the discovery and production of migraine treatments. Recent studies made by the ZosanoPharma have shown the effect of the Qtrypta on migraine suffering by reducing its frequency and pain. This holds a positive result for the potential of Qtrypta to be used as a long-term treatment solution for migraines.

Zosano has made progress on its lead candidate Qtrypta’s long term study data

The data obtained for this clinical trial was long-term data which is said to be published in the Journal of Headache and Pain. The safety and efficacy testing level of the trial suggested that it was tolerated consistently and showed no adverse effects while being tested in the Phase 2/3 ZOTRIP study.

The long-term data of the study showcased that the pain frequency of the migraine had reduced for the patients observed in the study. The migraine attacks occurred on average 2 times per month for the selected patients and after taking Qtrypta dosage they obtaining relief while facing no serious side effects. The migraine attacks only lasted 2 hours after the Qtryota dose was administered, this result showed an efficacy of 81% in migraine attacks. Furthermore, the freedom of pain was for 44% of the attacks and had also reduced the worst and troubling symptoms of migraine attack by 62% of attacks.

The administration of the dosage was majorly cutaneous application site where reactions were formed however these reactions were 95% mildly rated with 80% of the incidents of reaction resolved within 48 hours of application. This recent development has caused ZSAN stock shares to rise as it will with further milestones hopefully achieved in the future.